ArticleInvestigative and clinical urology2025
Nationwide surveillance of antimicrobial resistance for uncomplicated cystitis in 2023: Conducted by the Korean Association of Urogenital Tract Infection and Inflammation.
Article in Investigative and clinical urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Non-antibiotic treatments for the management of recurrent urinary tract infection in the multidrug resistance era: A narrative review.Investigative and clinical urology · 2026Review
- Trends in antimicrobial resistance of major gram-negative uropathogens, 2016-2024: A single center retrospective study.Investigative and clinical urology · 2026Article
- Emerging strategies for biofilm disruption in recurrent urinary tract infections.Investigative and clinical urology · 2026Review
- Disease complexity, not surgical approach, predicts outcomes in xanthogranulomatous pyelonephritis.Investigative and clinical urology · 2026Observational
- Carbapenem Resistance and ESBL-Producing Enterobacteriaceae in Patients with Urological Infections from 2012 to 2021 in Three Korean Hospitals.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThis study aimed to report the results of Korean Antimicrobial Resistance Monitoring System (KARMS) for uncomplicated cystitis (UC) in 2023. MATERIALS AND
methodsKARMS was established for the surveillance of antimicrobial resistance in urinary tract infections with the cooperation of Korean nationwide medical centers. Data from patients with UC have been collected in the web-based KARMS database. Demographic data, uropathogen distribution, and antimicrobial susceptibility of representative pathogens were analyzed.
resultsA total of 885 patients' data were collected in KARMS database. The mean patient age was 56.39±18.26 years. The number of postmenopausal and recurrent cystitis were 530 (61.1%) and 102 (11.5%), respectively.
conclusionsThese data provide information on the distribution of uropathogen and the status of antimicrobial resistance in UC of South Korea. In addition, KARMS will be a useful reference in the future through the continuous surveillance system construction over the years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.